PLGA-particle vaccine carrying TLR3/RIG-I ligand Riboxxim synergizes with immune checkpoint blockade for effective anti-cancer immunotherapy

Journal:
Nature Communications
Published:
DOI:
10.1038/s41467-021-23244-3
Affiliations:
8
Authors:
8
Institutions Authors Share
University of Konstanz, Germany
4.666667
0.58
Swiss Federal Institute of Technology Zurich (ETH Zurich), Switzerland
1.000000
0.13
Juntendo University, Japan
1.000000
0.13
Riboxx GmbH, Germany
0.500000
0.06
TU Dresden, Germany
0.500000
0.06
Biotechnology Institute Thurgau (BITg), Switzerland
0.333333
0.04